Novel and emerging diabetes mellitus drug therapies for the type 2 diabetes patient - Wikidata - wikimedia - TriplyDB

Novel and emerging diabetes mellitus drug therapies for the type 2 diabetes patient

Novel and emerging diabetes mellitus drug therapies for the type 2 diabetes patient

http://www.wikidata.org/entity/Q33759570

about

Poorly controlled type 2 diabetes is accompanied by significant morphological and ultrastructural changes in both erythrocytes and in thrombin-generated fibrin: implications for diagnostics Marine Bromophenol Derivative 3,4-Dibromo-5-(2-bromo-3,4-dihydroxy-6-isopropoxymethyl benzyl)benzene-1,2-diol Protects Hepatocytes from Lipid-Induced Cell Damage and Insulin Resistance via PTP1B Inhibition.Novel approaches to the treatment of hyperglycaemia in type 2 diabetes mellitus.Antidiabetic Effect of Tibetan Medicine Tang-Kang-Fu-San in db/db Mice via Activation of PI3K/Akt and AMPK Pathways.Antidiabetic Effect of Tibetan Medicine Tang-Kang-Fu-San on High-Fat Diet and Streptozotocin-Induced Type 2 Diabetic Rats.Oligonol promotes glucose uptake by modulating the insulin signaling pathway in insulin-resistant HepG2 cells via inhibiting protein tyrosine phosphatase 1B.

P2860

Q35189544-8B91FFBE-9770-4D85-A058-83433CAED005 Q35890756-C2834524-4277-4F47-A535-FCF799A98A8D Q40758518-4175E7D3-0969-43BB-82F3-F7A2ECD1F604 Q41537102-153B3972-099E-4A7B-8710-1CE66C8CEEC6 Q41622327-7976B56D-08A7-4E55-A08B-EB6825A8E8AC Q46287259-4A1BD6AA-8F71-4E9B-8DF8-3428854827B3

P2860

Novel and emerging diabetes mellitus drug therapies for the type 2 diabetes patient

http://www.wikidata.org/entity/Q33759570

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Novel and emerging diabetes mellitus drug therapies for the type 2 diabetes patient

@ast

Novel and emerging diabetes mellitus drug therapies for the type 2 diabetes patient

@en

type

label

Novel and emerging diabetes mellitus drug therapies for the type 2 diabetes patient

@ast

Novel and emerging diabetes mellitus drug therapies for the type 2 diabetes patient

@en

prefLabel

Novel and emerging diabetes mellitus drug therapies for the type 2 diabetes patient

@ast

Novel and emerging diabetes mellitus drug therapies for the type 2 diabetes patient

@en

P1433

Q33759570-F18CBA36-3F3D-426C-8132-2290114DA212

P1476

Q33759570-4CC64A8A-F10C-4623-8B9F-CB72B4D50BD2

P2093

Q33759570-B37C8814-B6B3-478D-98C9-4F81AECBF6A7

Q33759570-FEB13368-14D0-4EB2-BC44-22A0779FF3A8

P2860

Q33759570-00B8E0FE-73E9-414E-884A-74648E6F72F8

Q33759570-014BADB3-0C5E-4977-82E8-C6B3499C0B86

Q33759570-041EBB05-600F-4820-ADF0-CA482CCF0139

Q33759570-09AB7E58-4116-4301-A768-2D2F7E82F61D

Q33759570-0E695808-A939-46DE-BDA0-298B4D97767C

Q33759570-12EDB2F0-DA8A-4D59-A91F-0C2C78242D32

Q33759570-13EF5005-DE85-4926-8140-3C5E25E9C694

Q33759570-16C89E58-2BCE-4221-9A6A-34E47388638A

Q33759570-1D3F674B-74C9-4479-A92E-8DF2C4943F89

Q33759570-2051D1DA-2B45-47F7-B99C-BF386D114FBE

P304

Q33759570-5B62BD8D-6B8D-4A41-876E-55B214FD0C14

P31

Q33759570-EBF5FB48-F541-4667-974F-91491D6B795C

P356

Q33759570-63E6252E-5B56-4249-ADC9-9AFEAB3CA256

P433

Q33759570-4C8FBB66-2D3B-476E-AE28-B27E1D84C07E

P478

Q33759570-C2B4607B-9205-4802-801A-956745CEBFF3

P577

Q33759570-5E3F7B95-7859-45A8-BB11-1C94BCC25BC9

P5875

Q33759570-111B5EFE-805D-4484-96DC-5C2377211987

P698

Q33759570-F1404507-EFA5-4DE4-B7CC-132607DEC210

P921

Q33759570-11686CA1-6C55-4463-A2A7-E6D316569920

P932

Q33759570-2BBF2A36-2486-4C20-97C9-B85DE75E10CC

P356

P1433

World journal of diabetes

P1476

Novel and emerging diabetes mellitus drug therapies for the type 2 diabetes patient

@en

P2093

Charmaine D Rochester

http://www.w3.org/2001/XMLSchema#string

Oluwaranti Akiyode

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor

Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo.

Renal gluconeogenesis: its importance in human glucose homeostasis.

Current therapies and emerging drugs in the pipeline for type 2 diabetes.

The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy.

Glucose analog inhibitors of glycogen phosphorylases as potential antidiabetic agents: recent developments.

Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes

Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes.

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

P304

305-315

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4239/WJD.V5.I3.305

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2014-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263165679

http://www.w3.org/2001/XMLSchema#string

P698

24936252

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

4058735

http://www.w3.org/2001/XMLSchema#string